GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab

NEXT STORY
The United States IVD Market 2021-2026: COVID-19 as a Catalyst for an Acceleration in Research and Development
PREV STORY
Day One Receives Orphan Designation from the European Commission for DAY101 for the Treatment of Glioma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aptose Presents New Preclinical Data on CG-806 PAN-FLT3/PAN-BTK Inhibitor at ASH 60th Annual Meeting

Data elucidate unique ability of CG-806 to overcome resistance to other FLT3 inhibitors in ...

author_avatar
NASDAQ Market News

Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey Hackman as Chief Operating Officer

VANCOUVER, British Columbia, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a ...

author_avatar
NASDAQ Market News

Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis

New Cosentyx® (secukinumab) label to include dosing flexibility up to 300 mg, based on ...

author_avatar
NASDAQ Market News